title: [Dyslipidemia and the risk of kidney disease].
abstract: An abnormal lipid profile is very frequent in patients with kidney disease due to the well-known nephrotoxicity of lipids. During progression of chronic kidney disease, the excretion of triglycerides, LDL and proteins increases while the glomerular filtration rate declines. Blood lipoproteins and lipids are modulated depending on the type of treatment: hemodialysis, CAPD or renal transplant. We analyzed many studies on dyslipidemia in patients with kidney disease by comparing different therapies. The use of statins reduces protein excretion and hyperlipidemia as well as progression of chronic renal failure with a direct effect on mesangial cell proliferation. A decrease in total cholesterol and LDL occurs in hemodialysis patients, a decrease in LDL and an increase in HDL occur in CAPD patients, and a decrease in LDL and triglycerides is observed in renal transplant recipients; in the latter, graft survival increases without there being any relevant correlation with immunosuppressive treatment. In conclusion, we found that statins are useful to contrast the progression of chronic kidney disease and atherosclerosis in hemodialysis and CAPD patients and to reduce chronic allograft nephropathy in renal transplant recipients.
authors.affiliation: Divisione di Nefrologia Dialisi e Trapianto Renale, Azienda Ospedaliero Universitaria di Modena, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ligabue
authors.forename: F
authors.initials: F
authors.lastname: Cavazzini
authors.forename: A
authors.initials: A
authors.lastname: Albertazzi
mesh_terms: D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018450:Disease Progression; D050171:Dyslipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D019317:Evidence-Based Medicine; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000209:etiology; D016030:Kidney Transplantation / Q000009:adverse effects; D008074:Lipoproteins / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol